Adtran advances open networking at OIF’s ECOC 2025 demo with FSP 3000 OLS and coherent pluggables
25.9.2025 14:00:00 CEST | Business Wire | Press Release
Adtran today announced its role in the OIF’s open, multi-vendor interoperability demo at ECOC 2025 and highlighted its recent participation in the OIF Plugfest, where its 100ZR+ and 400ZRE coherent pluggables were validated across multiple hosts and platforms. On the ECOC show floor, 100Gbit/s, 400Gbit/s and 800Gbit/s signals generated by coherent pluggable optics will be transported over open line systems (OLS) in a disaggregated IPoDWDM environment. This includes a 300km Adtran FSP 3000 OLS multi-span link and Adtran 100ZR+ and 400ZRE coherent pluggable transceivers operating in third-party hosts and over both Adtran and third-party OLS. The live setup demonstrates how operators can scale capacity with simple turn-up and integrated visibility while preserving vendor choice. Together, these activities underscore Adtran’s commitment to openness at both the system and module levels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250922887315/en/
Adtran’s FSP 3000 OLS and coherent pluggables are set to be major talking points at ECOC 2025.
“Open optical networking is most effective when it empowers operators with flexibility and seamless integration,” said Ryan Schmidt, GM of optical transport at Adtran. “With our FSP 3000 open line system at the center of the ECOC demo, we’re showcasing a reliable 300km multi‑span link in a live multi-speed, multi-vendor environment, with simple activation and clear operational insight. This approach enables providers to expand capacity for cloud and AI workloads, reduce day-to-day complexity, improve energy efficiency and avoid vendor lock‑in while choosing the right technology for each role in the network.”
The ECOC showcase combines live demos and lab validation to show maturity in open optical networking. The FSP 3000 OLS delivers 100Gbit/s and 400Gbit/s services while supporting higher data rates up to 1.6Tbit/s. It uses high‑resolution flexgrid and colorless ROADMs with bidirectional inline amplifiers, plus automation and integrated monitoring, including automated span equalization. The OIF demo also features Adtran’s 100ZR+ and 400ZRE coherent pluggables operating over the FSP 3000 OLS in a multi‑vendor setup. The OIF Plugfest, held ahead of ECOC, extended interoperability testing to the module layer, where Adtran’s 100ZR+ and 400ZRE coherent pluggables were paired with diverse hosts and measurement systems. Adtran’s 100ZR+ and 400ZRE offer 0dBm output for strong performance and low power consumption. These activities demonstrate resilience, operational efficiency and vendor choice for operators building networks for AI, cloud and next‑generation services.
“Interoperability at the module level is essential for open, vendor-neutral networks,” commented Ross Saunders, GM of Optical Engines, Adtran. “Our first-time participation in the OIF Plugfest validated the performance of our 100ZR+ and 400ZRE coherent pluggables across multiple vendors and platforms, with results captured in OIF event materials. This complements the live ECOC demo and underscores the growing industry momentum toward open, multi-vendor optical infrastructures, giving operators confidence that ZR optics from different suppliers will work together in real deployments. It helps de-risk rollouts, support flexible sourcing and keep options open as providers scale to keep pace with AI-driven and cloud-native applications.”
Visitors to ECOC 2025 can view the OIF interoperability demo at booth C3425 from September 29 to October 1. Results from the OIF Plugfest will be published in OIF event materials following the show.
OIF at ECOC 2025: Bridging Gaps, Accelerating Innovation Through Industry-Wide Interoperability
Recognized for advancing interoperability, OIF returns to ECOC 2025 with a live, multi-vendor demo featuring 35 member companies. The demonstration spans optical, electrical, energy efficient and management interfaces, including 400ZR, 800ZR, OpenZR+, CEI-448G, CEI-224G, CEI-112G, Co-Packaging, CMIS, EEI and more. Through broad industry collaboration, OIF continues to close technical gaps and enable open, scalable networks. Visit OIF at booth #C3425 or learn more at www.oiforum.com/meetings-events/oif-ecoc-2025.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250922887315/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Peter Schuman
+1 256 963 6305
investor.relations@adtran.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom